Stock Ratings / Health Care / BON / earnings

NAII (34) MTEX (33) AKAN (54) BTMD (62) ⌘ Pro Terminal →

Bon Natural Life Limited (Class A) (BON) Next Earnings Date & Expected ±9.5% Move

$1.13 -0.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Bon Natural Life Limited (Class A) (BON) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $9.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-6.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BON)Realized 20D OHLCV Swing Band: ±9.5%

NEXT EST. WINDOW: Dec 29, 2026 (~57 DAYS)

Historical OHLCV Volatility ±9.5% Swing Band

±$0.11 Expected Swing

MODEL EARNINGS SETUP GAUGE

BON Quantitative Pre-Earnings Setup: 45/100

Trailing EPS: $4.25 • YoY Revenue Growth: -21.7%

Model Bullish Setup (45/100)Model Risk Weight (55/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-09-30	$18.7M	-$2.0M	$134.3K	20.8%
FY 2024	2024-09-30	$23.8M	$398.2K	-$7.7M	29.8%
FY 2023	2023-09-30	$29.5M	$4.6M	-$616.9K	20.8%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BON)

✓Walkthrough of BON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.72%📐 HORIZONTAL RANGE

2026-10-30O $1.15H $1.15L $1.10C $1.13VOL 23.2K

RES: $1.27SUP: $0.90SMA50: $1.15SMA200: $1.30

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BON Butterfly Map → + Track BON →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -21.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BON today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BON. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BON)

Health Care Rank #490 of 1016 ⚔️ NAII vs BON Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BON vs. NAII, MTEX, AKAN, BTMD)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bon Natural Life Limited (Class A) (BON) ranks #490 by composite RQD confidence (45/100, grade D) and #901 by equity capitalization ($9.2M). Within this direct 5-issuer industry benchmark cohort, BON leads on earnings valuation at N/A trailing P/E, while BTMD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. BTMD currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with BON at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BON ACTIVE Bon Natural Life Limited (Class A)	D	45/100	—	20.8%	—	-0.01%	$9.2M	Benchmark Subject
NAII Natural Alternatives International Inc.	E	34/100	—	7.2%	-10.8%	-4.31%	$6.9M	/naii-vs-bon →
MTEX Mannatech Incorporated	E	33/100	—	74.9%	-35.0%	-2.23%	$16.1M	/mtex-vs-bon →
AKAN Akanda Corp.	D+	54/100	—	—	—	+2.80%	$2.6M	/akan-vs-bon →
BTMD Biote Corp. (Class A)	C	62/100	—	—	85.0%	+1.74%	$42.0M	/btmd-vs-bon →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001816815

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Bon Natural Life Limited (Class A) (BON) reported GAAP revenue of $18.7M (-21.7% vs. FY2024 revenue of $23.8M , and -36.8% cumulative change since FY2023) , GAAP net income of -$2.0M, operating cash flow of $141.1K, and free cash flow of $134.3K (+101.7% YoY). On the balance sheet, BON closed FY2025 with $85.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$18.7M	-$2.0M	$141.1K	$134.3K	$85.2M	—
FY2024 (FY)	2024-09-30	$23.8M	$398.2K	-$7.7M	-$7.7M	—	—
FY2023 (FY)	2023-09-30	$29.5M	$4.6M	-$616.9K	-$616.9K	—	—

3. BON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Bon Natural Life Limited (Class A) (NASDAQ: BON) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.13 (-0.01% 1D, market cap $9.2M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BON ranks #490 in composite RQD confidence.

How does BON compare to NAII and MTEX in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), BON carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 20.8%, and ROIC of —. By comparison, NAII (Natural Alternatives International Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -10.8%, cap $6.9M) and MTEX (Mannatech Incorporated) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M). Among the 5-stock peer group, BON leads on earnings multiple (N/A) while BTMD leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BON?

Per BON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001816815), Bon Natural Life Limited (Class A) generated $18.7M in revenue (-21.7% YoY), -$2.0M in net income, and $134.3K in free cash flow against $85.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (21% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BON trading relative to its 50-day, 200-day, and 52-week technical levels?

BON last traded at $1.13 (-0.01% on volume of 1,385 shares), positioning the stock -1.74% below its 50-day simple moving average ($1.15) and -13.08% below its 200-day simple moving average ($1.30). Across its 52-week range of $0.95 to $2.06, BON sits at the 16.2% percentile with a 14-day RSI of 48.0 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($1.02 to $1.24).